Clinical Trial Update: Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab with bevacizumab, nab-paclitaxel, and carboplatin for untreated metastatic pulmonary sarcomatoid carcinoma (PSCs).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pulmonary Sarcomatoid Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN